(redirected from Pulmonary Arterial Pressure)
PAPPapanicolaou (Pap test or Pap smear; named for George Papanicolaou)
PAPPeople's Action Party (Singapore)
PAPPassword Authentication Protocol
PAPPatient Assistance Program
PAPPort-au-Prince (Haiti)
PAPPositive Airway Pressure
PAPPhysician Assistant Program (various locations)
PAPPort Authority Police (various locations)
PAPPicture and Picture
PAPPowers of Attorney for Property
PAPPrinter Access Protocol
PAPPolska Agencja Prasowa (Polish News Agency)
PAPPost-Activation Potentiation
PAPPublish Ahead of Print
PAPPhosphatidic Acid Phosphatase
PAPPublic Advisory Council
PAPPan-African Parliament (est. 2004)
PAPPulmonary Artery Pressure
PAPPhysical Activity Program (various locations)
PAPProcessed Animal Protein (feed)
PAPPharmaceutical Assistance Program (various locations)
PAPProtected Audio Path
PAPPublic Access Point
PAPPrivilege Access Password
PAPPractical Applications of Prolog
PAPPlastic Animation Paper
PAPPeople's Armed Police (China)
PAPPublic Awareness Program (various locations)
PAPPsychiatry and Allied Professions
PAPPulmonary Arterial Pressure
PAPPulmonary Alveolar Proteinosis
PAPPoker Affiliate Program (gambling)
PAPPharmacy Assistance Program
PAPPost Affiliate Pro (software)
PAPPre-Authorized Payment
PAPPersonal Auto Policy
PAPProtected Audio Path (Microsoft)
PAPProjet Annuel de Performance (French: Annual Performance Plan)
PAPPush Access Protocol (WAP)
PAPProstate Acid Phosphatase
PAPPlacental Alkaline Phosphatase (biology)
PAPPeople's Alliance Party (Solomon Islands)
PAPProspective Adoptive Parent
PAPPeruvian Aprista Party
PAPPurple Acid Phosphatase
PAPPublic Administration Project
PAPPoverty Alleviation Programme
PAPPolicy Agendas Project (University of Texas at Austin)
PAPPolicy Advisory Panel (various organizations)
PAPPrincipal Activity Plan (Australia)
PAPPolicy Administration Point (identity governance)
PAPPédagogie Active et Participative (French: Active and Participative Pedagogy)
PAPPerformance Assurance Plan
PAPPolice Accountability Project (University of Chicago; Illinois)
PAPPublic Access Profile
PAPPublic Art Policy (various locations)
PAPPage Avec Publicité (French: Page with Ads)
PAPPriority Action Programme
PAPProgramme d’Aide à la Publication (Publishing Aid Programme)
PAPPedigree Analysis Package
PAPProfessional Accredited Parliamentarian (credential)
PAPPacket-Level Procedure
PAPPersonnel Assurance Program
PAPParagon Adventure Park (Hazelton, PA)
PAPProcedure And Practice
PAPProgram Action Plan
PAPPrivate Access Provider
PAPPersonal Articles Policy (insurance)
PAPProduct Assurance Plan
PAPPerformance Assessment Plan
PAPPresent Active Participle (grammar)
PAPPrimes in Arithmetic Progression (mathematics)
PAPPurity, Aid, & Progress (Loyal Order of Moose)
PAPPersonnel Assistance Point
PAPPrograma de Asistencia al Paciente (Spanish)
PAPPhilosophical Association of the Philippines (Philippines)
PAPPacket Authentication Protocol
PAPPoluautomatska Puška (Croatian: semi-automatic rifle)
PAPPharmacy Administration and Practice
PAPPrêt d’Aide à l'Accession à la Propriété
PAPPerformance Assurance Procedures
PAPPower Angle Profile
PAPPeroxidase-Antiperoxidase smear test (medical term)
PAPPre-Approved Payments
PAPPalo Alto Philharmonic (California)
PAPPre-Allocation Porting
PAPPlant Administrative Procedure
PAPPayload Activity Plan
PAPProject Application Processor
PAPProduction Assurance Program
PAPProvider Access Point (ITU)
PAPPayload Attach Plate
PAPPolyaspartic Aliphatic Polyurea (concrete sealer)
PAPPlasma Arc Pyrolysis
PAPPublicly Available Price (Cap)
PAPProcess Assessment Procedure
PAPPorcine Actinobacillus Pleuropneumonia
PAPPredetermined Acceptance Probability
PAPPrimary Assembly Point
PAPPrion Amyloid Protein
PAPPrivate Administrative Procedure (similar to Notarial Protest)
PAPPast Assembly President
PAPProject-Affected Person/People
PAPProyectos Alternativos de Publicidad (Spanish: Alternative Advertising Projects)
References in periodicals archive ?
The Company's newly appointed Chief Executive Officer, Sandeep Yadav was previously COO of Cardiomems, one of the pioneers of the monitoring of pulmonary arterial pressure.
Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), six minutes walking distance and pulmonary arterial pressure were recorded after treatment.
Using invasive measures, Pulmonary Hypertension (PH) is defined as an increase in mean Pulmonary Arterial Pressure (PAP) to > 25 mmHg at rest as measured by Right Heart Catheterisation (RHC).
Comparison between patients who had systolic pulmonary arterial pressure of <35 mmHg or systolic pulmonary arterial pressure of >35 mmHg Parameters sPAP >35 mmHg (n=24) Mean [+ or -] SD Age (year) 59.
The assessment of pulmonary arterial pressure was made by measurement of maximum tricuspid insufficiency (TI), end-diastolic pulmonary insufficiency (PI), the ratio of acceleration time (AT) to ejection time (ET) (AT/ET), right atrial pressure (RAP) and contraction of vena cava inferior during inspiration [10].
For this study we considered pulmonary hypertension as peak systolic pulmonary arterial pressure equal or more than 35 mm Hg estimated by resting transthoracic echocardiography.
As pulmonary arterial pressure drops, the combination of low flow and desaturated blood causes myocardial ischaemia, especially during exertion.
Pulmonary arterial hypertension (PAH) is defined as the presence of a mean pulmonary arterial pressure (PAP) that exceeds 25 mmHg at rest or 30 mmHg during exercise.
Echocardiography revealed a right to left shunt through patent duct in the first case; suprasystemic pulmonary arterial pressure was estimated by using tricuspid regurgitation of moderate severity in the second case.
Collagen deposition in the pulmonary artery increases with elevated pulmonary arterial pressure (Stenmark et al.
Siobal's excellent review of pulmonary vasodilators found that long-term use of calcium channel blockers (diltiazem and nifedipine) reduced pulmonary arterial pressure and improved survival over a 5-year period, but cautioned that oral calcium channel blockers use was limited by their dose-related systemic vasodilator effects, a potential for hypotension, worsening right-ventricular function, increased intrapulmonary shunt, and hypoxemia.
Full browser ?